(453) A190, a new PPARα agonist loaded microemulsion for chemotherapy-induced peripheral neuropathy

Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) is a serious side effect of anticancer agents. There are no approved preventive or treatment interventions for the CIPN.1 Fenofibrate, a Peroxisome Proliferator-Activated Receptor-Alpha (PPAR-α) agonist has demonstrated neuroprotective and analgesic properties; however, its clinical utility is hindered by low receptor affinity and suboptimal bioavailability.2 A190, a highly selective non-fibrate PPAR-α agonist, offers a promising alternative, but is limited by poor solubility, resulting in reduced oral bioavailability and therapeutic efficacy.3